111 related articles for article (PubMed ID: 10326774)
1. Divided attention-enhancing effects of AF102B and THA in aging monkeys.
O'Neill J; Fitten LJ; Siembieda DW; Crawford KC; Halgren E; Fisher A; Refai D
Psychopharmacology (Berl); 1999 Apr; 143(2):123-30. PubMed ID: 10326774
[TBL] [Abstract][Full Text] [Related]
2. Reduction in distractibility with AF102B and THA in the macaque.
O'Neill J; Siembieda DW; Crawford KC; Halgren E; Fisher A; Fitten LJ
Pharmacol Biochem Behav; 2003 Sep; 76(2):301-6. PubMed ID: 14592682
[TBL] [Abstract][Full Text] [Related]
3. Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque.
Fitten LJ; Ortiz F; Siembieda DW; O'Neill J; Halgren E; Fisher A
J Neuropsychiatry Clin Neurosci; 1999; 11(1):79-85. PubMed ID: 9990560
[TBL] [Abstract][Full Text] [Related]
4. Effects of AF102B and tacrine on delayed match-to-sample in monkeys.
O'Neill J; Fitten LJ; Siembieda D; Halgren E; Kim E; Fisher A; Perryman K
Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):665-78. PubMed ID: 9682279
[TBL] [Abstract][Full Text] [Related]
5. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
Fisher A; Brandeis R; Karton I; Pittel Z; Gurwitz D; Haring R; Sapir M; Levy A; Heldman E
J Pharmacol Exp Ther; 1991 Apr; 257(1):392-403. PubMed ID: 2019998
[TBL] [Abstract][Full Text] [Related]
6. Effect of YM796, a novel muscarinic agonist, on the impairment of passive avoidance response in senescence-accelerated mice.
Suzuki M; Yamaguchi T; Ozawa Y; Iwai A; Yamamoto M
Pharmacol Biochem Behav; 1995 Aug; 51(4):623-6. PubMed ID: 7675834
[TBL] [Abstract][Full Text] [Related]
7. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats.
Fisher A; Brandeis R; Pittel Z; Karton I; Sapir M; Dachir S; Levy A; Heldman E
Neurosci Lett; 1989 Jul; 102(2-3):325-31. PubMed ID: 2812509
[TBL] [Abstract][Full Text] [Related]
8. Effects of a novel cholinergic M1 agonist, AF102B, on ambulation and water drinking behavior in rats.
Togashi H; Matsumoto M; Yoshioka M; Saito Y; Saito H
Hokkaido Igaku Zasshi; 1991 Jan; 66(1):59-66. PubMed ID: 2004736
[TBL] [Abstract][Full Text] [Related]
9. Effects of muscarinic and adrenergic agonism on auditory P300 in the macaque.
O'Neill J; Halgren E; Marinkovic K; Siembieda D; Refai D; Fitten LJ; Perryman K; Fisher A
Physiol Behav; 2000 Jul 1-15; 70(1-2):163-70. PubMed ID: 10978492
[TBL] [Abstract][Full Text] [Related]
10. Effects of (-)-S-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4,5]decane L-tartrate monohydrate (YM796), a novel muscarinic agonist, on disturbance of passive avoidance learning behavior in drug-treated and senescence-accelerated mice.
Suzuki M; Yamaguchi T; Ozawa Y; Ohyama M; Yamamoto M
J Pharmacol Exp Ther; 1995 Nov; 275(2):728-36. PubMed ID: 7473160
[TBL] [Abstract][Full Text] [Related]
11. Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.
Hatcher JP; Loudon JM; Hagan JJ; Clark MS
Psychopharmacology (Berl); 1998 Aug; 138(3-4):275-82. PubMed ID: 9725749
[TBL] [Abstract][Full Text] [Related]
12. Sympathoexcitatory action of a novel muscarinic receptor agonist, AF102B, and its blockade by pirenzepine.
Yoshioka M; Togashi H; Matsumoto M; Morii K; Saito H
Pharmacol Toxicol; 1990 Jul; 67(1):84-7. PubMed ID: 2395822
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the effects of the novel muscarinic receptor agonists L-689,660 and AF102B in tests of reference and working memory.
Dawson GR; Bayley P; Channell S; Iversen SD
Psychopharmacology (Berl); 1994 Jan; 113(3-4):361-8. PubMed ID: 7862846
[TBL] [Abstract][Full Text] [Related]
14. Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys.
Callahan MJ
Psychopharmacology (Berl); 1999 Jun; 144(3):234-8. PubMed ID: 10435389
[TBL] [Abstract][Full Text] [Related]
15. Reversal of age-related cognitive impairments by an M1 cholinergic agonist, AF102B.
Brandeis R; Dachir S; Sapir M; Levy A; Fisher A
Pharmacol Biochem Behav; 1990 May; 36(1):89-95. PubMed ID: 2349275
[TBL] [Abstract][Full Text] [Related]
16. Modulation of rhythmical slow activity, long-term potentiation and memory by muscarinic receptor agonists.
Iga Y; Arisawa H; Ise M; Yasuda H; Takeshita Y
Eur J Pharmacol; 1996 Jul; 308(1):13-9. PubMed ID: 8836627
[TBL] [Abstract][Full Text] [Related]
17. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
[TBL] [Abstract][Full Text] [Related]
18. Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine.
Terry AV; Buccafusco JJ; Borsini F; Leusch A
Psychopharmacology (Berl); 2002 Jul; 162(3):292-300. PubMed ID: 12122487
[TBL] [Abstract][Full Text] [Related]
19. [Effect of a muscarinic (M1) receptor agonist on sympathetic nerve activity in rats].
Saito Y
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):190-204. PubMed ID: 8509063
[TBL] [Abstract][Full Text] [Related]
20. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
Bymaster FP; Carter PA; Peters SC; Zhang W; Ward JS; Mitch CH; Calligaro DO; Whitesitt CA; DeLapp N; Shannon HE; Rimvall K; Jeppesen L; Sheardown MJ; Fink-Jensen A; Sauerberg P
Brain Res; 1998 Jun; 795(1-2):179-90. PubMed ID: 9622623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
